Evommune, Inc. (EVMN)vsVertex Pharmaceuticals Inc (VRTX)
EVMN
Evommune, Inc.
$19.82
-10.60%
HEALTHCARE · Cap: $717.49M
VRTX
Vertex Pharmaceuticals Inc
$446.83
+1.24%
HEALTHCARE · Cap: $107.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 122080% more annual revenue ($12.22B vs $10.00M). VRTX leads profitability with a 35.5% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 68/100 (B-).
EVMN
Avoid27
out of 100
Grade: F
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for EVMN.
Margin of Safety
+53.1%
Fair Value
$952.53
Current Price
$446.83
$505.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : EVMN
The strongest argument for EVMN centers on Debt/Equity, Altman Z-Score, Price/Book.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : EVMN
The primary concerns for EVMN are Revenue Growth, EPS Growth, Market Cap.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
EVMN profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
VRTX is growing revenue faster at 7.8% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VRTX scores higher overall (68/100 vs 27/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Evommune, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Evommune, Inc. is a forward-thinking biotechnology firm dedicated to advancing innovative therapeutics for immunological disorders, addressing critical unmet medical needs. The company boasts a promising pipeline and utilizes state-of-the-art research methodologies to optimize immune response and improve patient outcomes. It aims to establish itself as a leader in the dynamic immunotherapy landscape through rigorous scientific practices and strategic collaborations. As Evommune advances its clinical trials, it seeks to offer groundbreaking solutions that may redefine care standards in the field of immunology, ultimately enhancing the quality of life for patients.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?